Last reviewed · How we verify

NCT05371912

Enhancement of Behavioral and Cognitive Outcomes in Autism Spectrum Disorder Via Neurostimulation

Completed NA Results posted Last updated 26 November 2025
What this trial tests

NA trial testing Trans Cranial Magnetic Stimulation in Autism Spectrum Disorder in 16 participants. Completed in 1 February 2024.

Timeline
15 March 2022
Primary endpoint
31 October 2023
1 February 2024

Quick facts

Lead sponsorChristiana Care Health Services
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment16
Start date15 March 2022
Primary completion31 October 2023
Estimated completion1 February 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Christiana Care Health Services — full company profile →

Who can join

Adults 5 to 25, any sex, with Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

The Effects of rTMS on Reciprocal Social Awareness Primary · at baseline and 5 weeks of rTMS

Social Responsiveness Scale, Second Edition (SRS-2), Parent/Caregiver form; 65 items scored 0-3; total raw score range 0-195. Higher scores = greater social impairment. This study reports raw totals (not T-scores). Instrument: SRS-2

Baseline
GroupValue95% CI
Left IPL Stimulation68± 9.823
Right IPL Stimulation79.667± 14.624
Week 5
GroupValue95% CI
Left IPL Stimulation64.2± 5.310
Right IPL Stimulation74± 16.505
The Effects of rTMS on Reciprocal Rigid Patterns of Behavior Primary · at baseline and 5 weeks of rTMS

Repetitive Behavior Scale-Revised (RBS-R); 43 items scored 0-3; total raw score range 0-129. Higher scores = more severe restricted/repetitive behaviors. We report total raw scores.

Baseline
GroupValue95% CI
Left IPL Stimulation75.8± 11.212
Right IPL Stimulation86.667± 14.334
Week 5
GroupValue95% CI
Left IPL Stimulation75.4± 12.260
Right IPL Stimulation81.333± 12.879
The Effect of rTMS on Verbal Fluency Secondary · at baseline and 5 weeks of rTMS

Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency; scores converted to age-normed scaled scores (mean 10, SD 3). Higher scores = better verbal fluency/executive function. We report the Total Correct scaled score per the manual.

Baseline
GroupValue95% CI
Left IPL Stimulation5.8± 3.834
Right IPL Stimulation8.5± 7.778
Week 5
GroupValue95% CI
Left IPL Stimulation5.6± 2.793
Right IPL Stimulation9± 9.899
The Effects of rTMS on Executive Function Using Flanker Task Secondary · at baseline and 5 weeks of rTMS

NIH Toolbox Flanker Inhibitory Control and Attention; Age-Adjusted Standard Scores (mean 100, SD 15) reported. Higher scores = better inhibitory control/attention.

Baseline
GroupValue95% CI
Left IPL Stimulation66.8± 14.025
Right IPL Stimulation86± 22.996
Week 5
GroupValue95% CI
Left IPL Stimulation71.4± 16.742
Right IPL Stimulation83.833± 24.555
The Effects of rTMS on Executive Function Secondary · at baseline and 5 weeks of rTMS

NIH Toolbox Dimensional Change Card Sort (DCCS); Age-Adjusted Standard Scores (mean 100, SD 15) reported. Higher scores = better cognitive flexibility.

Baseline
GroupValue95% CI
Left IPL Stimulation77.4± 23.416
Right IPL Stimulation76.8± 23.784
Week 5
GroupValue95% CI
Left IPL Stimulation78.6± 17.544
Right IPL Stimulation80.2± 23.721

Sponsor's own description

Autism spectrum disorder (ASD) encompasses a range of limitations in reciprocal social and communicative milestones, as well as restrictive and/or repetitive patterns of behavior which lead to significant functional challenges impacting individuals throughout their lifespan. There are major shortcomings in the existing pharmacological interventions; they are of limited efficacy, target a subset of problematic behaviors, and fail to improve social cognition. To overcome these limitations and improve outcomes, the investigators study the use of neurostimulation to mitigate the social and cognitive manifestations of ASD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

Other Christiana Care Health Services trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05371912.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing